KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Gross Margin (2016 - 2025)

Historic Gross Margin for Travere Therapeutics (TVTX) over the last 12 years, with Q3 2025 value amounting to 99.04%.

  • Travere Therapeutics' Gross Margin rose 16200.0% to 99.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 97.63%, marking a year-over-year increase of 24200.0%. This contributed to the annual value of 96.68% for FY2024, which is 45600.0% up from last year.
  • Latest data reveals that Travere Therapeutics reported Gross Margin of 99.04% as of Q3 2025, which was up 16200.0% from 98.67% recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Gross Margin peaked at 99.32% during Q4 2021, and registered a low of 86.58% during Q1 2023.
  • Over the past 5 years, Travere Therapeutics' median Gross Margin value was 96.53% (recorded in 2023), while the average stood at 95.46%.
  • Per our database at Business Quant, Travere Therapeutics' Gross Margin plummeted by -71700bps in 2023 and then soared by 97800bps in 2024.
  • Over the past 5 years, Travere Therapeutics' Gross Margin (Quarter) stood at 99.32% in 2021, then fell by -2bps to 97.04% in 2022, then fell by -7bps to 89.87% in 2023, then grew by 7bps to 96.59% in 2024, then increased by 3bps to 99.04% in 2025.
  • Its last three reported values are 99.04% in Q3 2025, 98.67% for Q2 2025, and 94.28% during Q1 2025.